Biomarkers /
TPM4
Back to Biomarkers List
Associated Diseases
Overview
Tropomyosin 4 (TPM4) is a gene that encodes a protein that functions in the contractile system of striated and smooth muscles and the cytoskeleton of non-muscle cells. The protein also provides stability to actin filaments and regulates the access of other actin-binding proteins. Fusions, missense mutations, and silent mutations are observed in cancers such as breast cancer and intestinal cancer.
TPM4 is altered in 0.05% of all cancers with lung adenocarcinoma, prostate adenocarcinoma, acute myeloid leukemia, bladder urothelial carcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in TPM4 are TPM4-ALK Fusion (0.08%), TPM4-NTRK3 Fusion (0.03%), TPM4 R146P (0.52%), TPM4-DNAJB1 Fusion (0.01%), and TPM4-SMARCA4 Fusion (0.00%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.